AQUINOX PHARMACEUTICALS, INC 4
4 · AQUINOX PHARMACEUTICALS, INC · Filed Jun 5, 2017
Insider Transaction Report
Form 4
Main David
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2017-06-01$13.00/sh−6,000$77,988→ 71,530 total - Exercise/Conversion
Common Stock
2017-06-05$9.60/sh+3,625$34,800→ 75,155 total - Exercise/Conversion
Stock Option (Right to Buy)
2017-06-05−3,625→ 0 totalExercise: $9.60Exp: 2017-06-07→ Common Stock (3,625 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2017-06-01−6,000→ 9,625 totalExercise: $9.60Exp: 2017-06-07→ Common Stock (6,000 underlying) - Sale
Common Stock
2017-06-02$13.59/sh−6,000$81,560→ 71,530 total - Sale
Common Stock
2017-06-05$13.16/sh−3,625$47,696→ 71,530 total - Exercise/Conversion
Common Stock
2017-06-02$9.60/sh+6,000$57,600→ 77,530 total - Exercise/Conversion
Stock Option (Right to Buy(
2017-06-02−6,000→ 3,625 totalExercise: $9.60Exp: 2017-06-07→ Common Stock (6,000 underlying) - Exercise/Conversion
Common Stock
2017-06-01$9.60/sh+6,000$57,600→ 77,530 total
Footnotes (6)
- [F1]The exercise of options reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 15, 2017.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 15, 2017.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.82 to $13.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.45 to $13.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.04 to $13.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set in this footnote.
- [F6]The option is fully vested.